AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15450280 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT+AF Suppression (algorithm ON)
Number of subjects: 0
Study 15450280 — intervention group
Group type: COMPARATOR
Intervention: CRT only (algorithm OFF)
Number of subjects: 0
Study 11230488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b (IFNalpha2b)
Number of subjects: 107
Study 11230488 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-dose interferon alfa-2b (IFNalpha2b) and GMK
Number of subjects: 107
Study 9021810 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed regimen of 6-mercaptopurine and methotrexate
Number of subjects: 811
Study 9021810 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen during induction therapy
Number of subjects: 811
Study 9021810 — intervention group
Group type: COMPARATOR
Intervention: Regimen with cranial irradiation
Number of subjects: 811
Study 9021810 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk group-directed protocol 911
Number of subjects: 811
Study 9021810 — intervention group
Group type: COMPARATOR
Intervention: Protocol 811
Number of subjects: 811
Study 9021810 — intervention group
Group type: COMPARATOR
Intervention: Protocol 841
Number of subjects: 811
Study 9021810 — intervention group
Group type: COMPARATOR
Intervention: Protocol 874
Number of subjects: 811
Study 7950332 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (0.3% solution, 50 ul)
Number of subjects: 30
Study 7950332 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (same dose as norfloxacin)
Number of subjects: 30
Study 3296435 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiation and hormonotherapy (17-hydroxyprogesterone caproate)
Number of subjects: 76
Study 3296435 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving hormonotherapy)
Number of subjects: 76
Study 29500811 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 77
Study 29500811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 77
Study 29500811 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Pyridostigmine
Number of subjects: 77
Study 29500811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol + Pyridostigmine
Number of subjects: 77
Study 28738794 — intervention group
Group type: COMPARATOR
Intervention: Telephone-assisted self-help for parents and teachers
Number of subjects: 521
Study 28738794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy combined with psychoeducation
Number of subjects: 521
Study 28738794 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 521
Study 28738794 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 521
Study 28738794 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 521
Study 26518158 — intervention group
Group type: EXPERIMENTAL
Intervention: Xyloglucan
Number of subjects: 150
Study 26518158 — intervention group
Group type: COMPARATOR
Intervention: Diosmectite
Number of subjects: 150
Study 26518158 — intervention group
Group type: COMPARATOR
Intervention: S. bouliardii
Number of subjects: 150
Study 23453611 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone as submucosal injection
Number of subjects: 100
Study 23453611 — intervention group
Group type: COMPARATOR
Intervention: No steroid administration (control group)
Number of subjects: 100
Study 22533150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (Mimpara) accompanied by alfacalcidol (0.25 to 0.5 microg/day)
Number of subjects: 82
Study 22533150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (Mimpara) accompanied by alfacalcidol
Number of subjects: 82
Study 19117731 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (10mg/kg single dose upon introduction of anaesthesia)
Number of subjects: 616
Study 19117731 — intervention group
Group type: COMPARATOR
Intervention: Comparator (multiple doses of broad-spectrum antimicrobials for 4-6 days)
Number of subjects: 616
Study 17381494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-heparin emulsion (LHE) infusion
Number of subjects: 7
Study 17381494 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NaCl 0.9%) infusion (control)
Number of subjects: 7
Study 15018884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheek swab method (Group 1)
Number of subjects: 656
Study 15018884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheek swab method (Group 2)
Number of subjects: 656
Study 15018884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash swish method (Group 3)
Number of subjects: 656
Study 15018884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash swish method (Group 4)
Number of subjects: 656
Study 11394552 — intervention group
Group type: EXPERIMENTAL
Intervention: Major and minor stress assessment using Life Experiences Survey and Weekly Stress Inventory
Number of subjects: 183
Study 11394552 — intervention group
Group type: EXPERIMENTAL
Intervention: RAND 36‐Item Health Survey
Number of subjects: 183
Study 9932220 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (amoxicillin‐clavulanic acid, 1.5 g/24 h for 10 days)
Number of subjects: 35
Study 9932220 — intervention group
Group type: EXPERIMENTAL
Intervention: Small intestinal bacterial overgrowth syndrome (group 1)
Number of subjects: 35
Study 9932220 — intervention group
Group type: COMPARATOR
Intervention: No bacterial overgrowth (group 2)
Number of subjects: 35
Study 8563533 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 456
Study 8563533 — intervention group
Group type: COMPARATOR
Intervention: Mixed therapy (deep breathing exercises for low risk patients and incentive spirometry plus physiotherapy for high risk patients)
Number of subjects: 456
Study 8563533 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy for high risk patients
Number of subjects: 456
Study 2370647 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 24
Study 2370647 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 24
Study 7007837 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine 25 mg
Number of subjects: 23
Study 7007837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31852536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco cessation group behavioral intervention (5As: Ask, Advise, Assess, Assist, Arrange)
Number of subjects: 100
Study 31852536 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study 28921781 — intervention group
Group type: EXPERIMENTAL
Intervention: VGCV for 200 days
Number of subjects: 40
Study 28921781 — intervention group
Group type: COMPARATOR
Intervention: VGCV for 100 days followed by 3 doses of monthly CMV HIG
Number of subjects: 40
Study 25817172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) injection
Number of subjects: 70
Study 25817172 — intervention group
Group type: COMPARATOR
Intervention: Focal/grid laser treatment
Number of subjects: 70
Study 24557418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus capecitabine-cisplatin
Number of subjects: 202
Study 24557418 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus capecitabine-cisplatin
Number of subjects: 202
Study 23228527 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed music (PDM)
Number of subjects: 65
Study 23228527 — intervention group
Group type: COMPARATOR
Intervention: Headphones only to block ICU noise
Number of subjects: 65
Study 23228527 — intervention group
Group type: COMPARATOR
Intervention: Usual ICU care
Number of subjects: 65
Study 21514986 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Number of subjects: 40
Study 21514986 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 40
Study 21514986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 40
Study 21514986 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyTube
Number of subjects: 40
Study 21514986 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 40
Study 21514986 — intervention group
Group type: EXPERIMENTAL
Intervention: I-Gel
Number of subjects: 40
Study 18289149 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous paroxetine treatment (20 mg daily)
Number of subjects: 36
Study 18289149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent paroxetine treatment (20 mg daily)
Number of subjects: 36
Study 17044464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide 5-mononitrate (ISMN) 20 mg bid for 5 days
Number of subjects: 9
Study 17044464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12670617 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Coping Training (TCT)
Number of subjects: 43
Study 12670617 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact education (MC-E)
Number of subjects: 43
Study 12670617 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact relaxation (MC-R)
Number of subjects: 43
Study 12670617 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WC)
Number of subjects: 43
Study 11057781 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 56
Study 11057781 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified mineral talc
Number of subjects: 56
Study 11057781 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood
Number of subjects: 56
Study 11057781 — intervention group
Group type: COMPARATOR
Intervention: Aspiration only
Number of subjects: 56
Study 9564197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 28
Study 9564197 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study 7918123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment: three courses of neoadjuvant chemotherapy with cisplatin (100 mg/m2 i.v. d 1) and 5‐fluorouracil (1000 mg/m2/days 1‐5 by continuous i.v. infusion every 3 weeks) followed by conventional radiotherapy of 65‐70 Gy.
Number of subjects: 93
Study 7918123 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment: cisplatin (100 mg/m2 on days 1, 22, 43) given simultaneously with conventional radiotherapy of 65‐70 Gy.
Number of subjects: 93
Study 7918123 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous treatment
Number of subjects: 93
Study 7918123 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 93
Study 7918123 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 93
Study 2460431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockroach antigen immunotherapy (CRa‐IT)
Number of subjects: 28
Study 2460431 — intervention group
Group type: COMPARATOR
Intervention: Control immunotherapy (control-IT)
Number of subjects: 28
Study 29611504 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Number of subjects: 250
Study 29611504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar placebo tablet)
Number of subjects: 250
Study 28286095 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI)
Number of subjects: 141
Study 28286095 — intervention group
Group type: COMPARATOR
Intervention: White-light (WL) endoscopy
Number of subjects: 141
Study 25790454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-needling and exercise
Number of subjects: 80
Study 25790454 — intervention group
Group type: COMPARATOR
Intervention: Sham dry-needling and exercise
Number of subjects: 80
Study 23834882 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational seminar on antibiotic prescription for respiratory infections
Number of subjects: 171
Study 23834882 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 171
Study 21997904 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline irrigation plus separate budesonide nasal spray (group B)
Number of subjects: 60
Study 21997904 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline irrigation mixed with budesonide nasal spray (group C)
Number of subjects: 60
Study 21997904 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation alone (control group A)
Number of subjects: 60
Study 18477935 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.2 mg/kg/day) and propranolol (to decrease heart rate by 15%) for > or = 15 days
Number of subjects: 15
Study 18477935 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH/propranolol
Number of subjects: 15
Study 16503537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine and 20 microg/ml morphine (group L)
Number of subjects: 90
Study 16503537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine and 20 microg/ml morphine (group R)
Number of subjects: 90
Study 16503537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and 20 microg/ml morphine (group B)
Number of subjects: 90
Study 14551548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine solution infusion catheter
Number of subjects: 42
Study 14551548 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion catheter
Number of subjects: 42
Study 14551548 — intervention group
Group type: COMPARATOR
Intervention: No catheter (control group)
Number of subjects: 42
Study 14551548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both catheter groups (bupivacaine and saline)
Number of subjects: 42
Study 10620552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered peritoneal dialysis fluid (TB; 38 mmol/L of bicarbonate; pH 7.3)
Number of subjects: 15
Study 10620552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate-buffered peritoneal dialysis fluid (TBL; 25 mmol/L of bicarbonate/15 mmol/L of lactate; pH 7.3)
Number of subjects: 15
Study 10620552 — intervention group
Group type: COMPARATOR
Intervention: Acidic lactate-buffered peritoneal dialysis fluid (PD4; 40 mmol/L of lactate; pH 5.2)
Number of subjects: 15
Study 8711846 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovamycin
Number of subjects: 111
Study 8711846 — intervention group
Group type: COMPARATOR
Intervention: Amox-clav
Number of subjects: 111
Study 8042334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid sclerotherapy
Number of subjects: 1452
Study 8042334 — intervention group
Group type: COMPARATOR
Intervention: Flexible sclerotherapy
Number of subjects: 1452
Study 8042334 — intervention group
Group type: COMPARATOR
Intervention: Paravariceal sclerotherapy
Number of subjects: 1452
Study 8042334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravariceal sclerotherapy
Number of subjects: 1452
Study 8042334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sclerotherapy with splenectomy and devascularization
Number of subjects: 1452
Study 8042334 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1452
Study 8042334 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy sessions repeated every 2 weeks
Number of subjects: 1452
Study 8042334 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after continued bleeding post-sclerotherapy
Number of subjects: 1452
Study 8042334 — intervention group
Group type: COMPARATOR
Intervention: Different modalities of sclerotherapy
Number of subjects: 1452
Study 3043289 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 20
Study 3043289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30782886 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAM/DKP 75/25 mg
Number of subjects: 654
Study 30782886 — intervention group
Group type: COMPARATOR
Intervention: TRAM/paracetamol 75/650 mg
Number of subjects: 654
Study 30782886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 28285318 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine (Group S1)
Number of subjects: 60
Study 28285318 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg bupivacaine (Group S2)
Number of subjects: 60
Study 25483566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A/B coadministered with MenACWY-CRM
Number of subjects: 252
Study 25483566 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM only
Number of subjects: 252
Study 25483566 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A/B only
Number of subjects: 252
Study 24090821 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC)
Number of subjects: 183
Study 24090821 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 183
Study 20350671 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (SM)
Number of subjects: 15
Study 20350671 — intervention group
Group type: COMPARATOR
Intervention: No-intervention (NI)
Number of subjects: 15
Study 18348601 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX 380 mg
Number of subjects: 624
Study 18348601 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX 190 mg
Number of subjects: 624
Study 18348601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 16682719 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF (Colony-Stimulating Factors)
Number of subjects: 1
Study 16682719 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic CSF
Number of subjects: 1
Study 16682719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy regimens
Number of subjects: 1
Study 12664385 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-EL1 (Klean-Prep)
Number of subjects: 185
Study 12664385 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-EL2 (Endofalk)
Number of subjects: 185
Study 12664385 — intervention group
Group type: COMPARATOR
Intervention: NaP (Fleet Phospho-Soda)
Number of subjects: 185
Study 10630444 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched polymeric diet (42% of amino acid composition)
Number of subjects: 18
Study 10630444 — intervention group
Group type: COMPARATOR
Intervention: Standard low-glutamine polymeric diet (4% of amino acid composition)
Number of subjects: 18
Study 9013375 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin alone
Number of subjects: 48
Study 9013375 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin and finasteride
Number of subjects: 48
Study 9013375 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride alone
Number of subjects: 48
Study 9013375 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride and terazosin
Number of subjects: 48
Study 1349294 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose infusion
Number of subjects: 0
Study 1349294 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 1349294 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion study in persons with mild hypothyroidism (saline or 10% dextrose)
Number of subjects: 0
Study 6530305 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteration of nicotine level (specific dosage and duration not provided)
Number of subjects: 2
Study 6530305 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study 30772385 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide + Basal Insulin (BI)
Number of subjects: 181
Study 30772385 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea + Basal Insulin (BI)
Number of subjects: 181
Study 29718092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 668
Study 29718092 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 668
Study 28963845 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangle Decoction at 0.5 dose bid for 8 weeks
Number of subjects: 79
Study 28963845 — intervention group
Group type: COMPARATOR
Intervention: Cialis at 10 mg qd alt for 8 weeks
Number of subjects: 79
Study 28963845 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangle Decoction
Number of subjects: 79
Study 28963845 — intervention group
Group type: COMPARATOR
Intervention: Cialis
Number of subjects: 79
Study 25070961 — intervention group
Group type: EXPERIMENTAL
Intervention: ropinirole + physical therapy
Number of subjects: 0
Study 25070961 — intervention group
Group type: COMPARATOR
Intervention: placebo + physical therapy
Number of subjects: 0
Study 22551324 — intervention group
Group type: EXPERIMENTAL
Intervention: topical nipradilol
Number of subjects: 146
Study 22551324 — intervention group
Group type: COMPARATOR
Intervention: topical timolol
Number of subjects: 146
Study 22551324 — intervention group
Group type: EXPERIMENTAL
Intervention: topical β-blocker (nipradilol or timolol)
Number of subjects: 146
Study 20386073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20386073 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 200 mg
Number of subjects: 24
Study 20386073 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 300 mg
Number of subjects: 24
Study 20386073 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdoxovir
Number of subjects: 24
Study 20386073 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdoxovir plus Zidovudine 200 mg
Number of subjects: 24
Study 20386073 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdoxovir plus Zidovudine 300 mg
Number of subjects: 24
Study 18001618 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d
Number of subjects: 0
Study 18001618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17136932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led heart failure clinic
Number of subjects: 0
Study 11856098 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin loop TURP
Number of subjects: 70
Study 11856098 — intervention group
Group type: COMPARATOR
Intervention: Thick loop TUVRP
Number of subjects: 70
Study 11856098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 70
Study 10099977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose step-up FSH with IUI
Number of subjects: 97
Study 10099977 — intervention group
Group type: COMPARATOR
Intervention: Conventional FSH with IUI
Number of subjects: 97
Study 7486431 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglyconate (Maxon) suture
Number of subjects: 225